← Oncology Approval Tracker

FDA DECISION ·

Gavreto

pralsetinib · Blueprint Medicines

Accelerated approvalNew or expanded indicationMedullary thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Jul 20, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults and children ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Extended selective RET inhibition to a RET-mutant medullary thyroid cancer population under accelerated approval; FDA later withdrew this indication.

What research teams should watch

Record the mutation and medullary histology, and check the status of this specific indication before using the archive in a current summary.

PRIMARY RECORDS

Sources